Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 July 2025 | Story Dr Nitha Ramnath | Photo Supplied
Prof Vasu Reddy, Deputy Vice-Chancellor: Research and Internationalisation, and Prof Saleem Badat, Research Professor in the UFS Department of History, launch a new book honouring Ruth First’s activist legacy and scholarly impact.

On 16 July, during the Free State Arts Festival, the University of the Free State (UFS) launched Research and Activism: Ruth First & Activist Research, an incisive edited volume by Professors Vasu Reddy, Deputy Vice-Chancellor, Research and Internationalisation at the UFS, and Saleem Badat, Research Professor in the UFS Department of History

The event was facilitated by Prof Christian Williams, Associate Professor of Anthropology, with Prof Reddy delivering the keynote address and Dr Lazlo Passemiers, Senior Lecturer in History, serving as respondent.

The important new work pays tribute to Ruth First - South African freedom fighter, journalist, intellectual, and scholar-activist, who’s unflinching pursuit of justice continues to resonate. Far from a closed chapter in South Africa’s struggle history, First’s legacy remains a compelling call to action for contemporary scholars, activists, and institutions: to confront injustice, speak with conviction, and pursue research rooted in ethical action. 

 

A legacy of fearless scholarship

Ruth First’s activism was grounded in refusal to remain silent in the face of injustice. As a tenacious investigative journalist and public intellectual, she exposed the systemic violence of apartheid and challenged power through sharp incisive analysis and courageous advocacy. Her life, and her assassination by apartheid operatives in 1982, exemplify the personal and political costs of speaking truth to power.

Prof Vasu Reddy reflected that First “theorised, analysed, and connected the dots between racism, capitalism, and oppression, and refused to dilute her message for mass appeal.” Her words”, he said, “unsettled because they were true. Her activism “compels us to speak courageously, think critically, and act ethically. She turned ideas into instruments of liberation.”

 

Beyond the ivory tower 

With contributions from 17 scholars, the volume examines themes ranging from climate justice and activism in Marikana to the ethics of legal practice, community engagement, and the role of the university in social transformation. 

Prof Reddy emphasised that Ruth First’s example disrupts the traditional notions of academia. “Universities must be engines of social change, not ivory towers,” he argued. “Her legacy reminds us that activist research is about standing with the marginalised, and not merely studying them.” 

Dr Passemiers echoed this view, describing First as one of South Africa’s foremost examples of blending impactful activism with rigorous scholarship. “Her activism was often transnational, connecting South Africa’s liberation struggle with broader regional movements. This perspective is especially relevant today, as many of our challenges transcend national borders.”

He added that the book should be required reading for students in the social sciences and humanities, as it “challenges misconceptions about activist research and shows how scholarship can contribute meaningfully to public life, beyond academic debate.”

 

Redefining academic activism 

Prof Christian Williams underscored one of the book’s central provocations: to set a litmus test for genuine activist research. He argued that activism and scholarship can compete with one another, but should, following First’s example, be intersecting commitments. “There is no true academic neutrality,” he noted.

Members of the audience also touched on related themes pertaining to the role of universities in society, responding to the book’s content as narrated at the launch. For example, the collection interrogates how universities often claim to be ‘engaged’ while aligning primarily with business, the state, and elite interests. True activist research, the contributors argue, must connect with social movements and confront power, not shy away from it. Members of the audience reflected on this point, considering what it means for researchers to do activist research amidst attacks on social justice-oriented programmes in higher education globally. 

In Prof Reddy’s final comments, he returned to the importance of First for debates about the university’s role. “This is unfinished business. The story of Ruth First, and of activist scholarship, is not fully told”, says Prof Reddy. As he noted, Research and Activism offers both a tribute to Ruth First and a powerful reminder of the work still to be done. “Her life triggers us to think deeply about real-world issues, not as abstract concepts but as urgent matters of justice and humanity.”

Research and Activism: Ruth First & Activist Research is available for free download via the ESI Press website.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept